T. Rowe Price Associates’s BIOATLA INC BCAB Stock Holding History

T. Rowe Price Associates’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-256	Closed	-$45K	–	2933
2024 Q1	$45K	Buy	+256	New	+$31.8K	﹤0.01%	2883
2021 Q1	–	Sell	-12,770	Closed	-$21.7M	–	2846
2020 Q4	$21.7M	Buy	+12,770	New	+$21.3M	﹤0.01%	1209

Other funds holding BCAB

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

SAM

Scion Asset Management Saratoga, California $1.38B AUM 43.96% 1-Year Est. Return

T. Rowe Price Associates's BCAB Position: Q2 2024 in Review

T. Rowe Price Associates sold out of BIOATLA INC (BCAB) in Q2 2024, closing a stake of 256 shares — an estimated $45K sold.

T. Rowe Price Associates first reported a position in BCAB in Q4 2020 and held it in 2 quarters. The position peaked at $21.7M in Q4 2020. 80 funds tracked by Wall St. Rank hold BCAB as of Q2 2024.

T. Rowe Price Associates reported no remaining BIOATLA INC position as of Q2 2024 after selling out during the quarter.
T. Rowe Price Associates sold 256 BIOATLA INC shares in Q2 2024, an estimated $45K.
T. Rowe Price Associates first reported a position in BIOATLA INC in Q4 2020 and held it in 2 quarters.
T. Rowe Price Associates's BIOATLA INC position peaked at $21.7M in Q4 2020.
80 funds tracked by Wall St. Rank held BIOATLA INC as of Q2 2024.

Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.